Skip to main content

Table 4 Baseline data analysis of 1245 patients with different surgical mode

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables BCS (%) Mastectomy (%) Radical Mastectomy (%) χ2 P-value
Race      
White 297 (78.0%) 204 (80.0%) 467 (76.7%)   
Black 57 (15.0%) 38 (14.9%) 95 (15.6%) 2.12 0.714
Other 27 (7.0%) 13 (5.1%) 47 (7.7%)   
Age      
 ≤ 35 13 (3.4%) 16 (6.3%) 38 (6.2%)   
35 < age < 60 181 (47.5%) 132 (51.8%) 318 (52.2%) 8.373 0.079
 ≥ 60 187 (49.1%) 107 (42.0%) 253 (41.5%)   
Grade      
1 34 (8.9%) 20 (7.8%) 45 (7.4%) 6.528 0.163
2 173 (45.4%) 129 (50.6%) 258 (42.4%)   
3–4 174 (45.7%) 106 (41.6%) 306 (50.2%)   
Laterality      
Left 209 (54.9%) 130 (51.0%) 317 (52.1%) 1.115 0.573
Right 172 (45.1%) 125 (49.0%) 292 (48.0%)   
Marital      
Married 206 (54.1%) 138 (54.1%) 318 (52.2%)   
Unmarried 175 (45.9%) 117 (45.9%) 291 (47.8%) 0.438 0.803
Ethnic origin      
Spanish-Hispanic-Latino 43 (11.3%) 23 (9.0%) 70 (11.5%) 1.205 0.547
Non-Spanish-Hispanic-Latino 338 (88.7%) 232 (91.0%) 539 (88.5%)   
Histology      
IDC 326 (85.6%) 201 (80.0%) 49 (77.0%) 5.163 0.076
Non-IDC 55 (14.4%) 54 (20.0%) 113 (33.0%)   
T stage      
T1 91 (23.9%) 21 (8.2%) 41 (6.7%) 158,845  < 0.001
T2 22 (58.3%) 109 (42.7%) 238 (39.10%)   
T3 37 (9.7%) 59 (23.1%) 146 (24%)   
T4 31 (8.1%) 66 (25.9%) 184 (30.20%)   
N stage      
N0 126 (33.1%) 52 (20.4%) 30 (4.9%)   
N1 133 (34.9%) 124 (48.6%) 206 (33.80%) 192.317  < 0.001
N2 67 (17.6%) 41 (16.10%) 153 (25.10%)   
N3 55 (14.4%) 38 (14.90%) 220 (36.10%)   
Radiation      
Yes 22 (60.1%) 124 (48.6%) 351 (57.60%)   
No 15 (39.9%) 131 (51.40%) 258 (42.40%) 8.765 0.012
Chemotherapy      
Yes 20 (54.9%) 171 (69.50%) 423 (67.10%)   
No 17 (45.1%) 84 (30.50%) 186 (32.90%) 22.744  < 0.001
Subtype      
ER + /HER2− 276 (72.4%) 177 (69.4%) 416 (68.3%)   
ER + /HER2 +  54 (14.2%) 34 (13.3%) 101 (16.6%) 6.514 0.368
HER2 +  15 (3.9%) 11 (4.3%) 35 (5.7%)   
TNBC 36 (9.4%) 33 (12.9%) 57 (9.4%)   
ER      
Positive 329 (86.4%) 207 (81.2%) 514 (84.4%) 3.101 0.212
Negative 52 (13.6%) 48 (18.8%) 95 (15.6%)   
PR      
Positive 281 (73.8%) 176 (69.0%) 429 (70.4%) 1.97 0.373
Negative 100 (26.2%) 79 (31.0%) 180 (29.6%)   
HER2      
Positive 69 (18.1%) 45 (17.6%) 136 (22.3%) 3.786 0.151
Negative 312 (81.9%) 210 (82.4%) 473 (77.7%)   
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer